This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2019
ASCO GU 2019 Prostate Cancer
Conferences
ASCO GU 2019
Prostate Cancer
Kidney Cancer
Bladder Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
ASCO GU 2019 Prostate Cancer
Viewing 121-140 of 154 articles
ASCO GU 2019: LATITUDE Study - Final Analysis of Phase III Study in Patients with Newly Diagnosed High-Risk Metastatic Castration-Naïve Prostate Cancer
ASCO GU 2019: Outcome of Men with Relapses after Adjuvant BEP for Clinical Stage I Nonseminoma
ASCO GU 2019: A Phase II, Open-label, Multi-arm Study of TAS-115 for Castration-resistant Prostate Cancer Patients with Bone Metastases
ASCO GU 2019: Long-term Outcomes of Hypoxia Modification in Bladder Preservation: Update from BCON Trial
ASCO GU 2019: A Randomized Trial Comparing Fluorocholine-PET/CT with Conventional Imaging in Prostate Cancer
ASCO GU 2019: Discussion on: The ARAMIS Trial, the Final Analysis of LATITUDE Study, and the ARCHES Trial
ASCO GU 2019: Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2019: ARCHES Trial-Phase 3 Study of ADT with Enzalutamide in mHSPC
ASCO GU 2019: Keynote-365: Pembrolizumab Plus Olaparib in Docetaxel Pretreated Patients with Metastatic Castrate-resistant Prostate Cancer
ASCO GU 2019: Final Analysis of LATITUDE, A Phase III in Patients with Newly Diagnosed High-risk Metastatic Castration-naïve Prostate Cancer
ASCO GU 2019: Skeletal Related Events in CTRIAL-IE 13-21: Radium-223 in Combination with Enzalutamide for Patients with mCRPC
ASCO GU 2019: Phase II Study of Niraparib in Patients with Metastatic Castration-Resistant Prostate Cancer and Biallelic DNA-Repair Gene Defects : Preliminary Results of GALAHAD
ASCO GU 2019: Updated Analysis of Progression-Free Survival with First Subsequent Therapy and Safety in the SPARTAN Study of Apalutamide in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer
ASCO GU 2019: A Multicentric Phase II Randomized Trial of Docetaxel plus Enzalutamide versus Docetaxel as First Line Chemotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer: CHEIRON Study
ASCO GU 2019: Intensification Versus Deintensification in High-Risk Prostate Cancer
ASCO GU 2019: A Phase III Trial of Docetaxel versus Docetaxel and Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer: DORA
ASCO GU 2019: Cost-Effectiveness of Metastasis-Directed Therapy in the Setting of Oligometastatic Hormone-Sensitive Prostate Cancer
ASCO GU 2019: Quality of Life-Focused Decision-Making for Castrate-Sensitive Prostate Cancer
ARAMIS: Efficacy and Safety of Darolutamide in nmCRPC | ASCO GU 2019
ASCO GU 2019: Discussion on: Results of Checkmate 650 and Circulating Tumor Cell Number as a Transitional Surrogate Endpoint for Survival in mCRPC Trials
1
2
3
4
5
6
7
8
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free